• David & Buster’s (PLAY): Dave & Buster’s Entertainment, Inc. announced that its board of directors authorized the company to repurchase an additional $100 million of its stock under the company’s existing repurchase program through the end of fiscal 2018. As of July 31, the company had approximately $73 million remaining under that repurchase authorization.
  • Zumiez (ZUMZ): Zumiez Inc. announced that it expects to report earnings per diluted share in a range of $0.43-$0.48 on revenues of $236 to $241 million for the three months ending October 31, 2017. In comparison, Wall Street analysts were expecting, on average, for the company to report $0.43 in earnings per share on revenues of $227.9 million.
  • Target (TGT): Target Corporation reported on its Internet web site that it lowered prices on thousands of items in an effort to ensure its customers that they’re “getting a great, low price every day.”
  • Eli Lilly (LLY): Eli Lilly and Company announced that it experienced positive results from a Phase 3 study of the company’s galcanezumab drug to prevent migraines. The company said it plans to file for approval of the drug during the second half of this year, and that it will then seek approval from other regulatory agencies around the world.
  • Kura Oncology (KURA): Kura Oncology, Inc. announced that it experienced positive results from a Phase 2 study of the company’s tipifarnib drug for the treatment of skin cancer.
  • Roche (RHHBY): Roche Holding AG announced that it experienced disappointing results from a Phase 3 study of the company’s lampalizumab drug for age-related macular degeneration, which is associated with visual impairment.